Pfizer and BioNTech announced today that they plan to submit data to the Food and Drug Administration for three doses of their Covid-19 vaccine for children at least 6 months old up to children under 5 years old.
The companies released top-line results showing that three pediatric doses of their Covid-19 vaccine generated a comparable immune response in children as two full doses did in young adults — the primary end goal the FDA set
→ Continue reading at Politico
